Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuhiro Tanaka

Showing results (21-30 of 148) with videos related to

Pageof 15
Sort By:
American Journal of Physiology. Renal Physiology|October 29, 2014
Hypoxia as a key player in the AKI-to-CKD transitionShinji Tanaka, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|August 2, 2018
Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney diseaseSho Hasegawa, Tetsuhiro Tanaka, Masaomi Nangaku
Clinical and Experimental Pharmacology & Physiology|August 26, 2016
New insights into molecular mechanisms of epigenetic regulation in kidney diseaseImari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
F1000Research|March 4, 2016
Recent advances in understanding of chronic kidney diseaseJunna Yamaguchi, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|January 1, 2014
Role of hypoxia in progressive chronic kidney disease and implications for therapyKumi Shoji, Tetsuhiro Tanaka, Masaomi Nangaku
Therapeutics and Clinical Risk Management|February 25, 2021
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney DiseaseTaisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku
F1000Research|March 5, 2019
Recent advances in renal regenerationSho Hasegawa, Tetsuhiro Tanaka, Masaomi Nangaku
Contributions to Nephrology|April 17, 2019
Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney DiseaseMidori Sakashita, Tetsuhiro Tanaka, Masaomi Nangaku
Frontiers in Physiology|March 9, 2017
Renal Hypoxia in CKD; Pathophysiology and Detecting MethodsYosuke Hirakawa, Tetsuhiro Tanaka, Masaomi Nangaku
Expert Opinion on Drug Discovery|May 7, 2013
Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trialsYoshiki Higashijima, Tetsuhiro Tanaka, Masaomi Nangaku
Pageof 15

Showing results (21-30 of 148) with videos related to

Sort By:
Pageof 15
American Journal of Physiology. Renal Physiology|October 29, 2014
Hypoxia as a key player in the AKI-to-CKD transitionShinji Tanaka, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|August 2, 2018
Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney diseaseSho Hasegawa, Tetsuhiro Tanaka, Masaomi Nangaku
Clinical and Experimental Pharmacology & Physiology|August 26, 2016
New insights into molecular mechanisms of epigenetic regulation in kidney diseaseImari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
F1000Research|March 4, 2016
Recent advances in understanding of chronic kidney diseaseJunna Yamaguchi, Tetsuhiro Tanaka, Masaomi Nangaku
Current Opinion in Nephrology and Hypertension|January 1, 2014
Role of hypoxia in progressive chronic kidney disease and implications for therapyKumi Shoji, Tetsuhiro Tanaka, Masaomi Nangaku
Therapeutics and Clinical Risk Management|February 25, 2021
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney DiseaseTaisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku
F1000Research|March 5, 2019
Recent advances in renal regenerationSho Hasegawa, Tetsuhiro Tanaka, Masaomi Nangaku
Contributions to Nephrology|April 17, 2019
Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney DiseaseMidori Sakashita, Tetsuhiro Tanaka, Masaomi Nangaku
Frontiers in Physiology|March 9, 2017
Renal Hypoxia in CKD; Pathophysiology and Detecting MethodsYosuke Hirakawa, Tetsuhiro Tanaka, Masaomi Nangaku
Expert Opinion on Drug Discovery|May 7, 2013
Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trialsYoshiki Higashijima, Tetsuhiro Tanaka, Masaomi Nangaku
Pageof 15